Study of Tremfya in breast milk of breastfeeding women
Treatments studied
Part of Bones, joints & muscles, Digestive system, Skin clinical trials.
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease and take Tremfya regularly
- You have decided to keep taking Tremfya and breastfeed your baby
- You are at least 5 weeks after giving birth on the first day of the study
- You are mostly breastfeeding (no more than one bottle of formula per day) and plan to continue
- You have not used any other investigational drugs or live vaccines recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This study looks at how well guselkumab (Tremfya), a treatment for Crohn's disease and ulcerative colitis, works in everyday patients. Researchers will review medical records to see how long people stay on the medicine and how it helps their symptoms.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
This trial is for people with skin psoriasis who are already taking guselkumab (Tremfya) and have their shots spaced 9 weeks or longer apart. Researchers will see how well the skin is controlled with this longer interval.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.